Pharmacoeconomic evaluation on three different anti-hypertensive treatments

ZHANG Zhaowei; FANG Tianzi

doi:10.3969/j.issn.1006-0111.2018.02.021

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To compare three different anti-hypertension therapeutic projects by pharmacoeconomic evaluation and to find out the best therapeutic project. Methods Retrospective study was used.120 patients with hypertension were randomly assigned to group A (fosinopril sodium),group B(valsartan),group C(amlodipine besylate tablet),the therapeutic effects were observed and were evaluated by cost minimization analysis. Results The total efficiency of A,B,C group were 90.7%, 92.3%, 92.1% (P>0.05) respectively. The incidence of adverse reaction were 16.7%,7.7%,13.2%(P>0.05) respectively. The costs were 287.3 yuan, 378.7 yuan and 320.4 yuan respectively. Conclution The effectiveness of the three groups was similar. In terms of pharmacoeconomics, group A was the best therapeutic project.

Pharmacoeconomic evaluation on three different anti-hypertensive treatments

Department of Pharmacy, Jin Hua Central Hospital, Jin Hua 321000, China

Received Date: 2017-07-20

Rev Recd Date: 2017-11-03

Key words:

Abstract: Objective To compare three different anti-hypertension therapeutic projects by pharmacoeconomic evaluation and to find out the best therapeutic project. Methods Retrospective study was used.120 patients with hypertension were randomly assigned to group A (fosinopril sodium),group B(valsartan),group C(amlodipine besylate tablet),the therapeutic effects were observed and were evaluated by cost minimization analysis. Results The total efficiency of A,B,C group were 90.7%, 92.3%, 92.1% (P>0.05) respectively. The incidence of adverse reaction were 16.7%,7.7%,13.2%(P>0.05) respectively. The costs were 287.3 yuan, 378.7 yuan and 320.4 yuan respectively. Conclution The effectiveness of the three groups was similar. In terms of pharmacoeconomics, group A was the best therapeutic project.

HTML

Reference (6)

[1]	O'Shea PM,Griffin TP,Fitzgibbon M. Hypertension:the role of biochemistry In the diagnosis and management[J].Clin Chim Acta,2017,465:131-143.
[2]	杨春娥,张三奇,石玉,等.近年来高血压病药物及其综合治疗的概述[J].心脏杂志,2002,14(6):550-551.
[3]	Cesari M,Pedone C,Incalzi RA,et al. ACE-inhibition and physical function:results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study[J]. J Am Med Dir Assoc,2010,11(1):26-32.
[4]	Cesari M,Kritchevsky SB,Atkinson HH,et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers:Results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study[J].Am Heart J,2009,157(2):1-8.
[5]	Lim SY,Kim SW,Kim EJ,et al. Telmisartan versus valsartan in patients with hypertension:effects on cardiovascular, metabolic, and inflammatory parameters[J]. Kor Circul J,2011, 41(10):583.
[6]	曾晓勤.小剂量氨氯地平联合用药治疗高血压的疗效和安全性评价[J].中华临床医师杂志(电子版),2016,10(4):33-34.

[1]	O'Shea PM,Griffin TP,Fitzgibbon M. Hypertension:the role of biochemistry In the diagnosis and management[J].Clin Chim Acta,2017,465:131-143.
[2]	杨春娥,张三奇,石玉,等.近年来高血压病药物及其综合治疗的概述[J].心脏杂志,2002,14(6):550-551.
[3]	Cesari M,Pedone C,Incalzi RA,et al. ACE-inhibition and physical function:results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study[J]. J Am Med Dir Assoc,2010,11(1):26-32.
[4]	Cesari M,Kritchevsky SB,Atkinson HH,et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers:Results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study[J].Am Heart J,2009,157(2):1-8.
[5]	Lim SY,Kim SW,Kim EJ,et al. Telmisartan versus valsartan in patients with hypertension:effects on cardiovascular, metabolic, and inflammatory parameters[J]. Kor Circul J,2011, 41(10):583.
[6]	曾晓勤.小剂量氨氯地平联合用药治疗高血压的疗效和安全性评价[J].中华临床医师杂志(电子版),2016,10(4):33-34.

Message Board

Pharmacoeconomic evaluation on three different anti-hypertensive treatments

doi: 10.3969/j.issn.1006-0111.2018.02.021

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views